Facing numerous and dauntless hurdles, field research team tested the efficacy of the hepatitis E vaccine in Nepal. Read about the challenges and successes of the hepatitis E vaccine trial.
The South and Central Asia region has experienced extensive social, economic, and technological transformations, and it faces sometimes unpredictable problems in the areas of health, and natural disasters: HIV/AIDS, tuberculosis (TB), and malaria present health challenges; natural disasters such as tsunamis and earthquakes strain the region’s limited resources and lead to increased health and survival risks; isolated but ongoing conflicts jeopardize peace, stability, and development in the region.
In India, NIAID’s priorities for research include HIV/AIDS, with additional funding for research on HIV co-infections, filariasis, leishmania, and other diseases. Another of NIAID’s important research foci is drug-resistant tuberculosis. NIAID funds major research projects in Bangladesh that are focused on endemic diseases, such as cholera, amebiasis, and cryptosporidiosis; and on enteric pathogens, such as Vibrio cholerae and Entamoeba histolytica. NIAID also funds leprosy research in Nepal.
The U.S. government has science and technology agreements with both India and Bangladesh that facilitate research and collaboration. One of the most important and successful collaborations has been the Indo-U.S. Vaccine Action Program (VAP).
back to top
This information is not necessarily a complete list of NIAID research and NIAID-sponsored activities. It is intended to serve as an overview.
Last Updated September 18, 2014